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Abstract
Background: Genes might have different gene interactions in different cell conditions, which might be mapped
into different networks. Differential analysis of gene networks allows spotting condition-specific interactions that,
for instance, form disease networks if the conditions are a disease, such as cancer, and normal. This could
potentially allow developing better and subtly targeted drugs to cure cancer. Differential network analysis with
direct physical gene interactions needs to be explored in this endeavour.
Results: C3NET is a recently introduced information theory based gene network inference algorithm that infers
direct physical gene interactions from expression data, which was shown to give consistently higher inference
performances over various networks than its competitors. In this paper, we present, DC3net, an approach to
employ C3NET in inferring disease networks. We apply DC3net on a synthetic and real prostate cancer datasets,
which show promising results. With loose cutoffs, we predicted 18583 interactions from tumor and normal samples
in total. Although there are no reference interactions databases for the specific conditions of our samples in the
literature, we found verifications for 54 of our predicted direct physical interactions from only four of the biological
interaction databases. As an example, we predicted that RAD50 with TRF2 have prostate cancer specific interaction
that turned out to be having validation from the literature. It is known that RAD50 complex associates with TRF2 in
the S phase of cell cycle, which suggests that this predicted interaction may promote telomere maintenance in
tumor cells in order to allow tumor cells to divide indefinitely. Our enrichment analysis suggests that the identified
tumor specific gene interactions may be potentially important in driving the growth in prostate cancer.
Additionally, we found that the highest connected subnetwork of our predicted tumor specific network is enriched
for all proliferation genes, which further suggests that the genes in this network may serve in the process of
oncogenesis.
Conclusions: Our approach reveals disease specific interactions. It may help to make experimental follow-up
studies more cost and time efficient by prioritizing disease relevant parts of the global gene network.
Background
Treatment of a disease, such as cancer, requires under-
standing of normal cell physiology and pathogenesis
[1-3]. This goal is extremely difficult as cellular biomole-
cules are constantly interacting with each other in a
dynamic manner. These interactions are often repre-
sented as networks. Depending on the biological level of
interactions, the networks can be classified [4] as meta-
bolic networks, gene networks, protein networks, and so
on. The biological networks may also be classified
according to the type of interaction under consideration
such as direct physical gene interaction networks and
associative gene networks. By direct physical gene inter-
action we mean the interaction between a gene pair that
is not mediated by a third gene of the dataset under con-
sideration. In Figure 1, we have illustrated some of the
examples of direct and non-direct physical gene interac-
tions with explanations in the caption. Basically, two
genes are considered to be directly physically interacting
if they express together with no involvement of a third
gene between them, considering the fact that any other
molecules might be involved in the molecular process. In
fact, this definition is a result of the limitations inherent
in gene expression datasets, in which only mRNA
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any medium, provided the original work is properly cited.expressions are available. Since we do not have informa-
tion about any other molecule (protein, metabolites, etc.)
other than genes, we have to map a network of genes by
ignoring other molecules. The difference of direct physi-
cal interaction regarding associative networks is the spe-
cification of direct interaction of genes among them
rather than a group of coexpressed genes with any possi-
ble order of molecular reactions among the genes. By
associative network we refer to the weighted gene coex-
pression networks [5], where there is measurable relation
between the gene pair but the relation may well be over a
third or other genes. The task of inferring direct physical
interactions is more difficult to fulfil. Because in a very
complex and large network of interactions, for a gene
pair, it is more likely to predict an indirect interaction
from gene expression data as the indirect interactions
also get very close correlation values. Moreover, the
number of direct interactions are dramatically low con-
sidering the whole set of possible interactions in real
expression datasets. Despite the difficulty of this task, it is
of highest importance for drug development as it speci-
fies direct targets of gene interactions of interest.
Inferring gene networks of direct physical interactions
in vivo or in vitro via laboratory experiments provide
accurate detections, but it is very labour intensive pro-
cess and limited by the number of interactions that can
be detected experimentally [1]. However, current bio-
technology produces large-scale microarray gene expres-
sion datasets that can be used in computational
methods to supplement biochemical screens for interac-
tion partners. Nowadays, it is typical to come across, for
example, a homo sapiens expression dataset with around
25000 genes and 1000 samples. Working on the probe-
level for more resolution increases this number signifi-
cantly. The size might even be much higher when work-
ing on the intron and exon levels such as around 600
thousands of probes. Interpreting this abundance of
datasets requires powerful computational reverse engi-
neering algorithms and tools. Gene network inference
(GNI) algorithms showed significance advance in this
endeavour [6].
Among GNI algorithms, information theory based
ones [1,7-10] are computationally feasible to implement
on the very large-scale datasets with reasonable perfor-
mances [6]. They use mutual information (MI) [11] as
the measure of association between gene pairs. MI is
superior to linear correlation measures, e.g. Pearson, as
it is able to capture not only linear relationships
between gene pairs but also nonlinear relationships.
Among the information theory based methods, C3NET
has been shown to give consistently best inference per-
formances with low computational complexity [1] com-
paring other well known information theory based
methods such as Relevance Network [7], ARACNE [8],
CLR [9] and MRNET [10], and thus we employ it for
the differential gene network (DGN) analysis approach
of this study.
GNI algorithms predict gene networks with thousands
of interactions from gene expression datasets but it is
often difficult to interpret the resulting network itself.
The large size often makes it look like a hairball. It is dif-
ficult for a biologist to spot the interaction or groups of
interactions that are specifically related to the condition
of interest, such as cancer. It is also reported that mole-
cular interactions are dynamic with respect to different
cell conditions and vast majority of interactions detected
under one condition could not be detected under the
other condition [12,13]. As an experimental example,
70% of positive genetic interactions, which are resulting
in increased cell viability, under methyl methanesulfonate
treatment were not identified in the untreated samples
[12,13]. This biological phenomenon urges studies on the
differential network level to exploit this difference. Differ-
ential network analysis is shown to be useful in filtering
the networks to smaller size by comparing the pathways
in different conditions such as non-recurrent primary
Figure 1 Examples of direct physical gene interactions.
Examples of direct (A, C, E) and non-direct (B, D) physical gene
interactions. G, P are for gene and protein (or transcription factor),
respectively. Direct: Fig 1A. G1 encodes P1 that directly regulates
G2, Fig 1C. G1 encodes a kinase protein that phosphorylates P2 that
regulates G2, Fig 1E. G1 encodes P1 that makes protein complex
with P2 that is also encoded by G2. Non-direct: Fig 1B. G3 encodes
P3 that regulates both G1 and G2, Fig 1D. G1 encodes P1 that
regulates G3 that encodes P3 that regulates G2.
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Specifically, the research field disease networks [15] is
relatively new and a focal topic of interest. Here, by dis-
ease network we mean a network of biological interac-
tions that only appears in the disease state of a cell but
not in the normal state of a cell. This concept can be
called more generically as differential networks, meaning
the network of interactions that only appears in one con-
dition but not in other condition or conditions. Consid-
ering the comparisons among multiple conditions leads
to differential network analysis. A recent review on differ-
ential networking can be found in [4].
The methods developed for differential network analy-
sis are mostly based on coexpression networks [16-28].
A short summary of them can be found in [27]. For
example, a recent approach, called DiffCoEx [27] aims
identifying gene coexpression differences between multi-
ple conditions, which was developed based on Weighted
Gene Coexpression Network Analysis (WGCNA) [5,29].
DiffCoEx detects differentially coexpressed modules
using WGCNA. Nevertheless, it provides differentially
coexpressed modules that are not necessarily to be
direct physical interactions. Namely, DiffCoEx provides
much more general results by showing significantly
related genes in an associative way by clustering into
gene modules.
In this paper, we focus on the inference for differential
networks of only direct physical interactions by develop-
ing a comparison approach over C3NET. The developed
approach infers only direct physical interactions of dif-
ferential gene networks (DGN) from gene expression
datasets of multiple conditions. The approach differs
from others of [16-27] as it only provides direct physical
interactions in the inferred network but not providing
any kind of associative network or network modules. In
order to make the paper easier to read, we call the pre-
sented approach as DC3net (Differential C3NET) for the
rest of the paper. In general, DC3net infers the DGNs in
multiple conditions and also provides common network
of multiple conditions. Basically, having two cell condi-
tions under consideration, such as test and control (e.g.,
tumor and normal), two gene networks are inferred by
C3NET from the expression datasets and then com-
pared with the decision filter between the two. Details
of the decision filter can be seen in DC3net elaborated
section.
Using the predicted DGN on the real prostate cancer
dataset we further searched for tumor signatures with
enrichment analysis. We spotted the highest connected
subnetwork and discussed about its possible roles in
prostate cancer. We also pointed out the oncogenes in
the inferred differential and common networks that
show the possible role of oncogenes in the predicted
networks.
Results and Discussion
DC3net overview
The motivation to introduce DC3net is to find the
direct physical gene interactions that appear only in dis-
ease related cells but do not appear in normal healthy
cells so that we can infer only disease network of genes
and eliminate most of the interactions that is not related
to the disease of interest. The same approach can be
applied to any two different conditions cells to spot the
different and common gene interactions between them.
In the figure, the statistical term test might refer to
tumor samples and control to normal samples as we
have used in our exemplary prostate cancer dataset. As
can be seen in Figure 2, we provide three different net-
works as output, where the most important one is the
test differential network (difnet)t h a ti n c o r p o r a t e so n l y
the interactions of disease condition, which we call as
disease network. Second one is the common network of
the interactions of both conditions. This network shows
the essential interactions required for both conditions
and is a much more accurately predicted network, as
the interactions are the overlapping links that are
inferred independently in both cases. Third one is the
control difnet, which consists of interactions that
appears in the control case but not in the test case. It is
Figure 2 DC3net overview.A no u t l i n eo ft h ea p p r o a c hD C 3 n e t
with main processes.
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tions of healthy cell, which disappears in tumor case.
In order to be consistent and compact along the paper
we call all the networks of Figure 2 as follows: The net-
works that are inferred from test and control microarray
data are called as Tnet and Cnet respectively. We call
the three output networks with more generic names as
this approach can also be applied to two different tumor
types of samples to see the differences among them.
Therefore we call them as test difnet, common network,
and control difnet, respectively as seen in Figure 2. We
keep italicise them to avoid confusion.
The details of DC3net will be presented in section of
DC3net elaborated. Here, we give a brief explanation to
the outline of DC3net as illustrated in its simplest form
in Figure 2 for more general audience: Two different
m i c r o a r r a yg e n ee x p r e s s i o nd a t as e t s ,o n ea st e s t( e . g .
tumor case) and the other as control (e.g. normal or
healthy) are used as input. Applying C3NET to each of
the data sets, two different gene networks of direct phy-
sical interactions are inferred, which are called as Tnet
and Cnet, respectively. By comparing these two net-
works in the decision filtering step, first the common
network is inferred by selecting all the overlapping inter-
actions between the networks. Then test difnet is deter-
mined by selecting the interactions of Tnet that do not
have strong correlation values in the control case. Simi-
lar process is performed to determine control difnet
with respect to the test correlation matrix. The details
of all the steps can be found in section of DC3net
elaborated.
It is worth mentioning that, although we compare two
different networks of two different conditions, it is
pretty straightforward to apply DC3net to three or more
datasets of different conditions if required.
Performance of DC3net and biological validations
In this section, we discuss the application results
obtained using DC3net on a real prostate cancer dataset.
Before applying DC3net on the real dataset, we per-
formed analysis on a synthetic dataset to get an approxi-
mate idea on the inference performance of DC3net. We
observed that the inference results on the synthetic
datasets are very promising. In order not to distract the
reader’s attention from the results of the real applica-
tion, we present the details of the implementation and
results of the synthetic dataset in Additional File 1.
Applying DC3net on the prostate cancer and normal
datasets, we inferred the tumor (test) network, Tnet,
with 9653 interactions and the normal (control) net-
work, Cnet, with 8930 interactions. We inferred tumor
difnet with 2409 interactions, normal difnet with 2025
interactions and common network with 992 interactions,
w h e r ea l lt h ei n t e r a c t i o n so ft h e s en e t w o r k sa r e
provided in a tab delimited file format in the Additional
File 2. The Excel file is very useful to search some speci-
fic genes of interest and also sorting them with respect
to MI weight or gene name as required. Nevertheless,
the visualisations of these large networks are not read-
able when illustrated in a single page. Therefore we plot
only some of the interesting subnetworks from these
networks, which are all combined in a single pdf file
and available in Additional File 3. Visualisation of these
networks brings additional information, because the
highly connected subnetworks are not perceivable from
the Excel file. For example we plot top 250 genes with
respect to MI weight representing the strongest interac-
tions. We also plot, for instance, the hubs with order
greater than 3 and 2 to spot the hub genes. From that,
as an example, we have observed that the gene NONO
appears to be as a hub in normal difnet but disappears
in tumor difnet. Similar observations can be spotted by
a visual inspection among the plotted networks of Addi-
tional File 3.
In order to find biological verifications to support our
predicted interactions from the literature, we searched
some of the suitable databases such as Human Protein
Reference Database (HPRD) [30], BioGrid [31], ID-Serve
database in supplementary file 4 of [32] and also the B
cell interactome (BCI) [33,34]. We found 54 unique
interactions (5 in tumor difnet,3i nnormal difnet and
46 in common network) verified by the databases, which
confirms some of the predictions of C3NET. The num-
bers of verifications regarding the biological databases in
which they are found are tabulated in Table 1. We only
considered the experimentally verified interactions of
BCI as it also includes the predictions from which we
would have had much higher number of supports from
the whole set of it. The verified unique interactions and
which network category they belong to are provided in
Table 2. While searching for verifications, we have
directly looked up with respect to the gene names that
we have and also the gene names of the databases. The
number of verifications might be higher as genes have
in fact many different aliases. There are also many other
databases in which some more verification might be
found. Moreover, we did not see any specific database
Table 1 Number of validated predictions over various
databases
Databases Tumor difnet Normal difnet Common network
HPRD 2 2 6
BioGrid 2 2 5
ID-Serve 2 1 42
BCI 11 7 37
Number of inferred direct physical interactions verified by public databases
HPRD (Human Protein Reference Database), BioGrid, ID-Serve and BCI (B cell
interactome).
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as a reference interactions database. However, our gen-
eral literature search is performed thoroughly in those
four databases.
The networks of oncogenes
We have also investigated the interactions of important
genes in the prostate cancer data set. In this case study,
the oncogenes are considered as important genes regard-
ing the exemplary biological problem that is cancer. We
downloaded the oncogene list [35] from [36], which con-
sist of 436 oncogenes, and used it as a filter and then
selected the interactions if any one of the genes of the
gene pairs is in the list. We obtained subnetworks that
can be considered as oncogene networks for three of the
inferred differential networks. We plot these networks in
Additional File 3. This helps determining the role of
important genes in different conditions. From these ana-
lyses we observed that oncogenes are not only appearing
with edges in tumor case but they also appear with simi-
lar number of interactions in normal cell with different
gene partners. This implies that oncogenes might cause
disease when they interact with different genes than nor-
mal case. We observed that 913 and 836 interactions
with oncogenes available in Tnet and Cnet respectively.
We also detected those 218, 192 and 110 interactions
with oncogenes appear in tumor difnet, normal difnet
and common network, respectively, which are provided in
Additional File 3.
Relation of DC3net with differential expression analysis
We also look at the relation between standard differential
expression (DE) analysis [37] and our differential network
analysis with DC3net. MI incorporates linear and non-
linear relations and thus is a more general measure of
correlation regarding linear correlation measures used
for DE analysis. Therefore we expect, for example, top
ranked DE gene with lowest p-value to appear in the
tumor difnet but not necessarily with highest MI. Apply-
ing DE analysis in R [38] software package limma [37] to
the prostate cancer dataset, we obtained gene HPN as the
top ranked gene with p-value 4.41*10
-21 and adjusted
p-value 5.57*10
-17. Just as we expected, HPN appears in
our inferred tumor difnet but with relatively lower MI
value regarding other interactions. In tumor difnet,H P N
Table 2 Validations from literature for the predictions
Gene1 Gene2 Category
API5 DDX39 Tumor
MAPT PPP5C Tumor
TAP1 PSMB8 Tumor
TERF2 RAD50 Tumor
MYC RPL3 Tumor
CCND1 NCOA3 Normal
TOB1 PABPC1 Normal
PRKG1 SF1 Normal
C1R C1S Common
MYC CNTN2 Common
COL4A1 COL4A2 Common
UBC CTNNB1 Common
EGR2 EGR3 Common
HLA-G HLA-A Common
HLA-G HLA-F Common
KLK3 KLK2 Common
DST KRT5 Common
UBE2G2 MGRN1 Common
MT1E MT1H Common
MT1X MT1H Common
ESR1 POU4F1 Common
PSME2 PSMB1 Common
PSMB1 PSMB3 Common
PSMB4 PSMC1 Common
RPL15 RPL10A Common
RPL22 RPL10A Common
RPS17 RPL10A Common
RPS13 RPL12 Common
RPS7 RPL12 Common
RPL11 RPL24 Common
RPS14 RPL29 Common
RPL12 RPL31 Common
RPL6 RPL31 Common
RPS18 RPL31 Common
RPS23 RPL31 Common
RPL27A RPL34 Common
RPL24 RPL35 Common
RPL30 RPL35 Common
RPS12 RPL37 Common
RPS9 RPL8 Common
RPS12 RPL9 Common
RPS16 RPS11 Common
RPS8 RPS13 Common
RPL7 RPS15A Common
RPL10 RPS2 Common
RPS20 RPS24 Common
RPL13 RPS28 Common
RPL23 RPS3A Common
RPLP0 RPS4X Common
RPL29 RPS5 Common
RPL27 RPS7 Common
Table 2 Validations from literature for the predictions
(Continued)
RPL32 RPS7 Common
RPS6 RPS8 Common
COL1A2 SPARC Common
The experimentally verified unique direct physical interactions from the
databases and their predicted categories.
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ing the ranks 1065 and 1696, out of 2410 interactions,
with MI values 0.52 and 0.39 where the top ranked (rank
1) interaction has the MI value 1.33. We also look at the
top ranked interaction of tumor difnet in DE genes. In
general, the gene pairs of a differential interaction of
tumor difnet is not necessarily to be DE genes as they
might interact with different partners in different condi-
tions and thus might not appear as DE gene. However, it
is likely that at least one of them might also be DE gene.
The top ranked interaction in tumor difnet is in between
COL6A1 and PAX8. They have p-values of 0.00077 and
0.05 that supports our expectations, as they are reason-
ably low p-values but not among lowest. We also look at
the lowest rank interaction of tumor difnet,w h i c hi si n
between LTBP2 and COL5A2. They have p-values of
0.006 and 0.004 that reflects our expectations as no
strong relation exist from differential interactions to DE
genes as we see top and lowest ranked interactions have
similar p-values. This might be due to, in addition to
algorithmic difference, the property of MI capturing also
the non-linear effects upon the linear ones.
Biological analysis of the predicted differential gene
interactions
Significant amount of the interactions identified by DC3net
have been shown to be already validated in the literature as
shown in Table 2. These are the verifications considering
only the direct physical interactions. Among strong inter-
actions observed in both tumor and normal state was the
interaction between proteases C1r and C1s. In fact both of
these proteases form part of a complex with C1q, to make
the classical pathway of the eukaryotic complement system.
In serum, C1r and C1s were also found to be associated
only with C1q [39]. This also indicates that the classical
pathway of the complement system may still be operative
in tumor cells, which tend to evade the immune system.
Another important finding of this analysis was a strong
association observed between beta catenin (CTNNB1) and
UBC ubiquitin protein. Cytosolic beta-catenin regulates
cell-to-cell adhesion however, in nucleus it acts as a com-
ponent of the Wnt signaling pathway [40]. The beta-cate-
nin signaling pathway regulates cell proliferation and is
often over-expressed in cancer. Under normal conditions
in the absence of wnt ligand, beta-catenin is degraded by
ubiquitin mediated degradation that explains its interaction
with UBC as observed in normal prostate however, its
association in cancer indicates that beta-catenin may also
be efficiently degraded in prostate cancer.
Among many interactions that were inferred by
DC3net, the interaction between RAD50 and TRF2 is
very interesting and potent. In fact, this interaction has
been experimentally validated. Immuno-fluorescence
and mass spectrophotometric studies has demonstrated
that RAD50 complex associates with TRF2 in the S
phase of cell cycle [41,42]. This is an interesting finding
as this interaction was tumor specific interaction thus
raising the possibility that this interaction may promote
telomere maintenance in tumor cells in order to allow
tumor cells to divide indefinitely.
Similarly, a strong interaction between cyclin D1 and
NCOA3 a coactivator of steroid receptor coactivators
(SRC) family was found. It has been demonstrated that
cyclin D1 interacts with SRC-1 family coactivators in a
ligand-independent fashion through a motif that resembles
the leucine-rich coactivator binding motif of nuclear
hormone receptors [43]. By acting as a bridging factor
between estrogen receptor (ER) and SRCs, cyclin D1 can
recruit SRC-family coactivators to ER in the absence of
ligand. It is possible that in normal cells cyclin D1 associ-
ates with NCOA3 and activate ER leading to enhanced ER
dependent transcription necessary for the growth of estro-
gen responsive tissue. However, what is the physiological
relevance of this interaction in prostate needs to be estab-
lished. Similarly it has been shown that in the process of
eukaryotic protein translation, a transcriptional termina-
tion complex that harbours Tob mediates binding with
polyadenylate-binding protein PABPC1 [44].
Gene ontology analysis
To understand the relevance and physiological significance
of the identified interactions, gene ontology analyses using
MetaCore from GeneGo Inc. was performed. To limit the
analyses to the most significant gene interactions only top
100 interactions/edges were taken for these analyses in
each case.
In enrichment by protein function analysis for both
tumor and normal case the transcription factors were
among the top hit with z-score for tumor = 4.661; nor-
mal = 3.912 (Table 1 and 2), indicating the housekeep-
ing function in the life of a cell, irrespective of whether
they are normal or transformed.
In geneGO processes networks, among the top 10 hits in
tumor network was “proliferation positive regulation_cell
growth; p = 1.18 e-3” and “apoptosis_Antiapoptosis
mediated by external signals via PIK3/AKT; p = 5.55 e-3”
(Additional File 4, Figure S1), indicating that the identified
tumor specific gene interactions may be potentially impor-
tant in driving the growth in prostate cancer. In addition,
gene interactions important for translation_Translation
initiation process were also significantly enriched (p =
1.76 e-3) in tumors highlighting the need to synthesize
proteins involved in tumor growth at a faster rate. Inter-
estingly, in the normal gene interaction dataset, “Cell cyc-
le_G1-S growth factor regulation” was among the top 10
hits (p = 5.74 e-4) (Additional File 4, Figure S2), indicating
that the normal gene interactions are involved in robust
regulation of cell cycle in normal cells. Among these,
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enriched (p = 8.68 e-3), which employs that the primary
immune defence to remove any cancer cells remains
operative and intact in normal cellular state and one
important way by which cancer cells evade host immune
response is by overcoming the ability of natural killer cells
to phagocytise tumor cells.
Among the top 10 ontology-molecular functions between
tumor and normal “fructose 1,6 bisphosphate 1-phospha-
tase activity” (p = 8.53 e-5) and “fructose 2,6 bisphosphate
2-phosphatase activity” (p = 5.5 e-5) respectively, showed a
significant enrichment (Additional File 4, Figure S3 & S4).
It is important to note that fructose 1,6 bisphosphate 1-
phosphatase is a key regulatory enzyme of gluconeogen-
esis, it is therefore vital for cancer cells to proliferate in an
accelerated manner. Fructose 6 bisphosphate 2-phospha-
tase, however, regulates the concentration of the key posi-
tive allosteric effector of glycolysis, fructose 2,6-
bisphosphate thereby is important in the regulation of
energy metabolism in normal cells. Also tumor dataset
was enriched in sequence specific DNA binding transcrip-
tion factor activity (p = 3.33 e-4) while sequence specific
DNA binding (p = 2.2 e-6) was enriched in normal gene-
interactions, indicating an enhanced requirement of acti-
vation of transcription machinery in cancer cells to meet
increased proliferation rate. Among the top 10 common,
both the normal and tumor gene interactions, normal vital
functions important for cell growth and survival such as
“peptide receptor activity, G-protein coupled” (p = 2.37 e-
4) was enriched (Additional File 4, Figure S5).
Analysis of GO processes in normal dataset resulted in
regulation of transport;( p=1 . 2 9e - 1 7 ) ,regulation of locali-
zation; (p = 1.9 e-17), regulation of secretion; (p = 5.95
e-17) and cell-cell signalling; (p = 2.57 e-15), as the most
significant processes underscoring the important of these
processes in normal cellular functioning (Additional File 4,
Figure S6). In tumor gene interactions, however, two of the
most significant hits among top 10 were response to hor-
mone stimulus; (p = 2.35 e-13) and response to endogenous
stimulus; (p = 3.84 e-13) (Additional File 4, Figure S7).
Since prostate cancer is a well-known hormone responsive
tumor, the unbiased identification of this GO process vali-
dates the relevance of these gene interaction networks
identified by DC3net. This not only correlates to this gene
network with disease state but also identifies potential
important gene interaction in prostate cancer datasets;
many of these gene interactions may be important in regu-
lating normal cell growth and also in driving prostate
cancer.
The highest connected subnetwork of tumor differential
network
Here we discuss about the highest connected subnet-
work of tumor difnet as seen in Figure 3. This
subnetwork might have an important role in prostate
cancer. In fact, we found that this network demonstrates
a very strong correlation among others; with the “Prolif-
eration_positive regulation cell proliferation” which
further validates that genes in this network may serve in
the process of oncogenesis [45,46] (Additional File 4,
Figure S8). In addition, among GO molecular functions,
“growth factor activity” was found to be significantly
activated indicating, that this network may stimulate
growth of cancer cells (Additional File 4, Figure S9).
This was further advocated by the GO processes where
“Enzyme linked receptor protein signalling” pathway was
among the top hits indicating the growth factors are
operative via receptor kinase functions to promote the
process of oncogenesis (Additional File 4, Figure S10).
Conclusions
We showed the usage of C3NET on differential network
analysis by developing the approach DC3net. The per-
formance of it has been studied on synthetic and also
on real dataset and found some verification from the lit-
erature. Since the performance of C3NET was well stu-
died and shown to have consistently better performance
than its competitors, the literature validations of the
predictions and also synthetic analysis suggest that
DC3net is a promising candidate to infer disease net-
works of direct physical gene interactions. It may be
applied to any expression datasets of multiple conditions
to spot the interactions of specific and also common
cases. This would allow dealing with much smaller and
important networks than a whole of a predicted network
that mostly appears like a hairball in which case it
would be discouragingly hard to find an interesting
interaction for the specific problem. Therefore DC3net
helps to save resources and allows spotting better drug
targets to cure a disease. A future work would be con-
sidering into account transcription factor binding and
sequence data along with DC3net for more specific and
boosted results.
Methods
DC3net elaborated
Here we describe our differential network approach with
all its details over Figure 4. A general outline of DC3net
was described previously. The two data sets of different
conditions are first preprocessed with RMA [47] nor-
malization and copula transformation [8,48] as in [1].
The ideal case for comparison of the two data sets is
when their gene or probe names are exactly the same
and their number of samples is equal or close to each
other. If the gene names are not the same, e.g. test and
control data sets have also different genes in the set,
then it is up to user how to proceed. In any case,
DC3net gives the differential network whereas the
Altay et al. BMC Bioinformatics 2011, 12:296
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Page 7 of 12different genes will automatically appear in the difnets if
they have significant MI values. Depends on the experi-
mental design of microarray dataset both cases might be
suitable. If the different genes is not useful to see in the
differential network then at the beginning of preproces-
sing step all the different genes can be eliminated and
then the comparison is performed with the common
genes that are available in both of the networks. Or they
m a yb ea tl e a s tb eh i g h l i g h t e di nt h er e s u l t a n tn e t w o r k
for considering the problem.
Regarding the number of samples, again the ideal case
is having exactly the same samples in both datasets.
However, it is usually not the case in the available biolo-
gical datasets. If the datasets are from patients, namely
steady state, of two different conditions (e.g. tumor and
healthy) the only considerations is the number of samples
in both conditions. In this case the closer the number of
samples the higher the accuracy of difnets and common
network because the inference performance of C3NET
varies with the sample size as in the case of all other gene
network inference algorithms [1,6,49]. If the data sets
consists of time-series samples of two different condi-
tions then one needs to consider that time points as well
along with the number of samples. Because two different
time intervals of two different conditions might result
difnets that incorporate not only the difference in two
conditions but also the differences of time positions and
intervals. Therefore we can say that this analysis is more
sensitive while applying DC3net to time-series data sets
and one should be vigilant while interpreting the results.
We then estimate the MI matrices using the parametric
Gaussian estimator as described in [50,51] and used in
[1] where the details can be found. These MI matrices
are square adjacency matrices where the correlation mea-
sure, MI, correspond to weight of interaction for each
gene pair and the diagonals are set to zero ignoring the
self-interactions. The higher the MI value the more likely
that the gene pair is interacting. All gene pairs would
have a MI value but some are apparently because of
noise and thus nonsignificant. We also compute row wise
ranked versions of these MI matrices in descending order
as rank 1 corresponds to the highest MI value in a row of
the matrix. This ranked matrices will be used in compar-
ing and filtering the networks at the comparison step.
Then C3NET is applied to these MI matrices as
explained in section C3NET of Additional File 1 to infer
gene networks of direct physical interactions of test and
control datasets independently, where the inferred net-
works are called as Tnet and Cnet respectively. At this
point we have all the components to compare the two
networks to find differential networks, difnets,a n dcom-
mon network. We now start describing the core part of
DC3net, which is the comparison step, as can be fol-
lowed in Figure 4.
Although we describe inferring the test difnet in Fig-
ure 4, the same process can also be applied by
Figure 3 The highest connected subnetwork in tumor difnet. As the highest connected subnetwork with 105 edges in tumor difnet might
have an important role in the prostate tumor cell.
Altay et al. BMC Bioinformatics 2011, 12:296
http://www.biomedcentral.com/1471-2105/12/296
Page 8 of 12considering Cnet and Tnet in place of each other to find
control difnet. The following decision process is per-
formed for each gene pair of Tnet: As seen in the com-
parison part of Figure 4, there are four conditions that
all must be provided at the same time for an edge to be
decided in test difnet. Lets say we will decide whether
one of the interactions of Tnet,e . g .g e n eA( gA)w i t h
gene B (gB), only appears in Tnet but not in control
case. We first check whether the potential interaction
gA to gB of the ranked control MI matrix is one of top
ranked interactions or not. If the rank of gA and gB in
the row of gA of the ranked control MI matrix is greater
than the predefined cut-off parameter, rankdif, then the
first condition holds for deciding it as a difnet interac-
tion. In our case study we set rankdif as 2000 since
there are about 12000 genes in total in the dataset and
we consider that the rank decrease to 2000 is reasonably
high to be strict in the decision process. If one wants a
stricter difnet then rankdif needs to be increased for
example to 8000 in our case. One may also reduce
Figure 4 DC3net in detail. DC3net is elaborated by illustrating all the processes involved.
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Page 9 of 12rankdif, for example to around 200 and get more differ-
ent interactions but with loose difnet with more edges
in it. We then look at the second condition that is the
change in MI value of the interaction from gA to gB in
the control MI matrix. If the MI value of the gene pair
gA and gB in the control MI matrix is less than the pre-
defined cut-off parameter MIdif then second condition
also holds to decide the interaction as in difnet. MIdif in
this example is defined as MIrate times the maximum
MI value of the row of gA in the control MI matrix.
Here MIrate is defined as the rate decrease that is speci-
fied by the user and in our case study we set it as 0.6.
Depends on how strict the differential network is
desired for inferring, one may increase or decrease this
cut-off parameter. The previous two conditions com-
pared the values of the interaction from gA to gB but
we also need to compare the values from gB to gA as
the edge would be inferred from either of the genes
since MI is a bidirectional measure. In the third condi-
tion, if the rank of the interaction from gB to gA in the
r o wo fg Bi nt h er a n k e dcontrol MI matrix is greater
than the cut-off parameter, rankdif, then the third con-
dition also holds. For the fourth condition, if the MI
value of the interaction from gB to gA in the control MI
matrix is less than the parameter MIdif then the fourth
condition also holds. Note that here, MIdif is set with
respect to the row of gB in the control MI matrix and
thus may be denoted as MIdifb (the previous one of the
condition two could be denoted as MIdifa). In this parti-
cular example of gA and gB,i ff o u ro ft h ec o n d i t i o n s
hold together then we infer this interaction as in test
difnet and continue to perform same filtering process
f o ra l lo t h e rg e n ep a i r si nTnet.I nt h ee n d ,w eg e ttest
difnet as a smaller subnetwork of Tnet.T h i sw a st h e
description of inferring test difnet (or tumor difnet in
our case study). However, inferring the control or nor-
mal difnet can be performed by applying the same pro-
cedure described for Tnet after interchanging the place
of Cnet and Tnet in the above descriptions. We now
continue by describing the inference of the common
network.
Lets now start to describe the way we infer the common
network. The strictest way of finding the common net-
work is to search for all the same interactions between
Tnet and Cnet and then infer the common network.O n
the other hand one may choose not to be that strict and
consider also their ranks and MI value decreases in the
other dataset. More precisely, one needs to follow the
manner of the difnet process described above but change
the comparison operator of rank difference, rankdif, from
greater to less and for the MIdif from less to greater as
can be seen in Figure 4. Furthermore, we only look at
either of the two conditions, rather than all the four con-
ditions together, from gA to gB or gB to gA. The logical
OR operator in Figure 4 represents this process. Then
following the difnet process with the changes described
above will result the common network.A g a i nt h ec u t - o f f
parameters need to be arranged by the user regarding the
biological datasets dealt with. One may also assign differ-
ent cut-off parameter values for difnet and common net-
work inference to place a gap in the inferred networks for
more accurate results by avoiding decision around the
cut-off boundaries. Moreover, one may also choose to
use only one of the cut-off parameters (either rank or MI
value) for looser or maybe stricter cases. In our case
study on the prostate cancer data, we set different para-
meters such that rankdif as 200 and MIdif as 0.85 for
more strict results while inferring the common network.
Note that although we described the approach DC3net
for the analysis of two different cell conditions, it is
straightforward to extend it to multiple conditions in a
similar fashion. It is worth mentioning that, in its current
form, we infer the common network with respect to the
common interactions of tumor difnet comparing to con-
trol (normal) MI matrix, since our focus is the disease
case. Nevertheless, if desired, a more general common
network can also be inferred by adding one more step to
the inference of it as described above. In that case, inter-
actions of Cnet is compared to the tumor (test) MI
matrix in the same way as performed for the test case
and then the filtered interactions added onto the common
network.
We provide some more details on C3NET and the appli-
cation of DC3net over a synthetic dataset in Additional
File 1 where as we give the related references [52-55] of
them in this main paper.
On the other hand, it is always beneficial to mention
about the limitations of any algorithm for users. One of
the main limitations of any differential network analysis
method, including DC3net, is that they need similar
number of samples of multiple conditions for the most
accurate comparison possible. It is because the inference
performances of GNI methods, including C3NET, are
affected by sample sizes. DC3net may still be applied on
expression datasets with different sample sizes as long
as one keeps in mind the fact that the results might
have been biased by the difference in sample sizes.
Another limitation is that microarray experiments do
n o ta l w a y sp r o v i d et h ee x a c ts a m ep r o b e sa ss o m eo f
them may be distorted during experiment. Therefore,
because of the imprecision of available the datasets,
some, though few, genes may not be compared with the
other condition. Those genes cannot be considered con-
dition specific and needs further attention. The general
limitations of inference algorithms apply on our differ-
ential analysis. Particularly, DC3net inherently deals
with only the very core, but not all, of the true underly-
ing network because of the conservative causal core
Altay et al. BMC Bioinformatics 2011, 12:296
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Page 10 of 12property of C3NET but in return gains in prediction
accuracy.
The biological dataset
In order to perform a real application of the presented
approach DC3net, we used the dataset of [56] that was
used to study clinical prostate cancer behaviour. This
dataset is widely used in the literature and also quite
suitable for differential network analysis as it has almost
equal number of samples for tumor and normal cases.
The data were gathered by analysing 235 radical prosta-
tectomy specimens from patients undergoing surgery
between 1995 and 1997. It was reported that 65 of these
samples had tumors on opposing sides of the tissue spe-
cimen. High-quality expression profiles were derived
from 52 of these prostate tumors and 50 nontumor (e.g.
normal) prostate samples with oligonucleotide microar-
rays containing probes for approximately 12,600 genes
and ESTs [56]. The raw data has been downloaded from
http://www-genome.wi.mit.edu/MPR/prostate. As the
number of samples in tumor and normal are close, we
are able avoid the sample size effect differences on the
inference of both datasets.
Additional material
Additional file 1: Details of synthetic dataset analysis and C3NET.
Additional file 2: All the inferred differential and common networks.
All the inferred interactions of difnets and common network in tab-
delimited format. (.xls) with MI edge weight and rank information.
Additional file 3: Plots of the inferred differential and common
networks.Apdf file consisting of the plots for interesting subnetworks
of the difnets and common network. It also includes all the subnetworks
of these networks with oncogenes.
Additional file 4: Enrichment analysis illustrations using MetaCore
from GeneGo Inc.. Each figure in the file is referred in the main text.
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